URGN Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

30.030

Open

30.030

VWAP

29.61

Vol

600.04K

Mkt Cap

1.41B

Low

29.340

Amount

17.77M

EV/EBITDA(TTM)

--

Total Shares

48.72M

EV

1.46B

EV/OCF(TTM)

--

P/S(TTM)

10.04

UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

Show More

Events Timeline

(ET)

2026-05-15

08:40:00

UroGen Pharma UGN-103 Achieves 94.5% Durability of Response at Six Months

2026-05-13 (ET)

2026-05-13

09:20:00

UroGen Pharma Reports 36-Month DOR of 64.5% for Zusduri

2026-05-06 (ET)

2026-05-06

09:50:00

UroGen Q1 Revenue at $50.96M, Below Expectations

2026-03-30 (ET)

2026-03-30

09:10:00

UroGen Pharma Publishes Key Trial Results for Zusduri

2026-03-13 (ET)

2026-03-13

08:10:00

UroGen Pharma Grants Inducement RSUs to 11 New Employees

News

Fool

Superstring Capital Reduces Stake in UroGen Pharma

NASDAQ.COM

05-23NASDAQ.COM

Superstring Capital Reduces Stake in UroGen Pharma

Yahoo Finance

05-13Yahoo Finance

Healthcare Stocks Rise 0.8% on NYSE Healthcare Index

Yahoo Finance

05-11Yahoo Finance

Urogen Pharma CMO Mark Schoenberg Sells Shares

seekingalpha

05-06seekingalpha

UroGen Pharma Reports Strong Q1 2026 Earnings with Significant ZUSDURI Growth

seekingalpha

05-06seekingalpha

UroGen Pharma Q1 Earnings Beat Expectations

4 Analyst Rating

Wall Street analysts forecast URGN stock price to rise

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

31.00

Averages

40.25

High

55.00

Current: 0.000

Low

31.00

Averages

40.25

High

55.00

Ladenburg

NULL

to

Buy

initiated

$43

AI Analysis

2026-05-11

Reason

Ladenburg

Price Target

$43

AI Analysis

2026-05-11

initiated

NULL

to

Buy

Reason

Ladenburg assumed coverage of UroGen Pharma with a Buy rating and $43 price target. The firm says the strong early commercial adoption of Zusduri provides a \"significantly de-risking path to profitability\" for UroGen.

H.C. Wainwright

Raghuram Selvaraju

Buy

maintain

$40 -> $45

2026-05-11

Reason

H.C. Wainwright

Raghuram Selvaraju

Price Target

$40 -> $45

2026-05-11

maintain

Buy

Reason

H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on UroGen Pharma to $45 from $40 and keeps a Buy rating on the shares. The firm views the company's Q1 report as solid, saying the commercial launch of Zusduri continues to accelerate.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for URGN

Unlock Now

Valuation Metrics

The current forward P/E ratio for Urogen Pharma Ltd (URGN.O) is 0.00, compared to its 5-year average forward P/E of -4.30. For a more detailed relative valuation and DCF analysis to assess Urogen Pharma Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-4.30

Current PE

0.00

Overvalued PE

-1.31

Undervalued PE

-7.28

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-4.89

Current EV/EBITDA

-9.00

Overvalued EV/EBITDA

-0.63

Undervalued EV/EBITDA

-9.15

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

3.82

Current PS

3.33

Overvalued PS

5.18

Undervalued PS

2.46

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

recomend a stock in the biotech field

Intellectia · 46 candidates

Industry: Biotechnology & Medical ResearchQuarter Revenue Yoy Growth: >= 0.0%Analyst Consensus: Strong Buy, Moderate BuyMoving Average Relationship: PriceAboveMA20, PriceCrossAboveMA20

Ticker

Name

Market Cap$

Precision BioSciences Inc

215.19M

Septerna Inc

1.12B

Compugen Ltd

269.48M

CG Oncology Inc

6.53B

Lexicon Pharmaceuticals Inc

1.08B

Cytokinetics Inc

10.48B

stocks with 500 percent upside by 2027

Intellectia · 88 candidates

Quarter Revenue Yoy Growth: >= 0.0%Analyst Consensus: Strong Buy, Moderate BuyQuarter Eps Yoy Growth: >= 0.0%Target Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA200Is Optionable: True

Ticker

Name

Market Cap$

Precision BioSciences Inc

211.58M

Orchestra Biomed Holdings Inc

243.12M

Septerna Inc

1.12B

Compugen Ltd

267.59M

Lexicon Pharmaceuticals Inc

1.07B

Verrica Pharmaceuticals Inc

122.83M

what is a good stock to buy into right now

Intellectia · 142 candidates

Market Cap: >= 1000.00MRegion: USPrice: >= $10.00Quarter Revenue Yoy Growth: >= 3.0%Analyst Consensus: Moderate Buy, Strong BuyRsi Category: moderateBeta: LowRisk, ModerateRisk, HighRisk, NegativeBetaMoving Average Relationship: PriceAboveMA20

Ticker

Name

Market Cap$

Arrowhead Pharmaceuticals Inc

10.49B

BROOKFIELD ASSET MANAGEMENT LTD

79.34B

Vir Biotechnology Inc

1.61B

Madrigal Pharmaceuticals Inc

11.58B

Sprott Inc

3.27B

Turning Point Brands Inc

1.57B

tomorrow’s top pick premarket

Intellectia · 6 candidates

Market Cap: >= 1000.00MRegion: USList Exchange: XNYS, XNAS, XASEOne Day Rise Prob: >= 60One Day Predict Return: >= 1.5%Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

Kontoor Brands Inc

3.63B

Wix.Com Ltd

3.87B

Urogen Pharma Ltd

1.02B

Best Buy Co Inc

12.98B

Veeva Systems Inc

29.92B

CrowdStrike Holdings Inc

93.78B

Whales Holding URGN

Migdal Mutual Funds Ltd.

TCG Crossover Management, LLC

Paradigm Biocapital Advisors LP

Jefferies Financial Group Inc.

Tang Capital Management, LLC

RTW Investments, LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is Urogen Pharma Ltd (URGN) stock price today?

The current price of URGN is 29.46 USD — it has increased 1.97

What is Urogen Pharma Ltd (URGN)'s business?

UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

What is the price predicton of URGN Stock?

Wall Street analysts forecast URGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for URGN is40.25 USD with a low forecast of 31.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Urogen Pharma Ltd (URGN)'s revenue for the last quarter?

Urogen Pharma Ltd revenue for the last quarter amounts to 50.96M USD, increased 151.60

What is Urogen Pharma Ltd (URGN)'s earnings per share (EPS) for the last quarter?

Urogen Pharma Ltd. EPS for the last quarter amounts to -0.47 USD, decreased -48.91

How many employees does Urogen Pharma Ltd (URGN). have?

Urogen Pharma Ltd (URGN) has 291 emplpoyees as of May 28 2026.

What is Urogen Pharma Ltd (URGN) market cap?

Today URGN has the market capitalization of 1.41B USD.